- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06716463
Prédire l'échec de l'assistance ventilatoire non invasive à l'aide d'une surveillance non invasive chez les patients non intubés présentant une insuffisance respiratoire hypoxémique aiguë ou un échec post-extubation. l’étude PRÉVISION (PREVISION)
Prédire l'échec de l'assistance ventilatoire non invasive à l'aide d'une surveillance non invasive chez les patients non intubés présentant une insuffisance respiratoire hypoxémique aiguë ou un échec post-extubation : l'étude PREVISION
The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
Aperçu de l'étude
Statut
Description détaillée
This is a single-center, prospective, physiological study.
The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.
The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.
The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.
HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.
The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.
After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
La description
Inclusion Criteria:
- Age of ≥ 18 years
- Using NIV or HFNC anywhere in the hospital
Exclusion Criteria:
- Chronic CO2 retention
- Neuromuscular disorder
- Requiring home NIV (CPAP or BIPAP)
- Tracheostomy
- Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Difference in regional ventilation distribution (%)
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diaphragm or parasternal intercostal muscle thickening fraction
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Rapid shallow breathing index (RSBI) in mL/breaths/min
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The intensive care respiratory distress observation scale (IC-RDOS)
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The work of breathing scale
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Self-report of dyspnea visual analog scale (D-VAS)
Délai: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Unity Health Toronto
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .